Tiziana Life Sciences PLC B. Riley Virtual Neuroscience Investor Conference
April 27 2021 - 2:00AM
RNS Non-Regulatory
TIDMTILS
Tiziana Life Sciences PLC
27 April 2021
Tiziana Life Sciences to participate in a Fireside Chat
on 28 April 2021 at 10:30 a.m. EDT
NEW YORK and LONDON - 27 April 2021 (GLOBE NEWSWIRE) - Tiziana
Life Sciences plc (NASDAQ: TLSA/ LSE: TILS) ("Tiziana" or the
"Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation and infectious diseases,
today announced its CEO and CSO Dr. Kunwar Shailubhai and the chair
of its Scientific Advisory Committee, Dr Howard Weiner, will
participate in a fireside chat via a video link on Wednesday, 28
April 2021 at 10:30 a.m. EDT (US and Canada) to provide updates on
the Company. Please note that only information which is already in
the public domain will be discussed.
Date: Wednesday, 28 April 2021
Time: 10:30 a.m. - 11:00 a.m. Eastern Daylight Savings Time (US and Canada)
Webcast: https://www.webcaster4.com/Webcast/Page/2433/41045
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that
focuses on the discovery and development of novel molecules to
treat human disease in oncology and immunology. In addition to
Milciclib, the Company is also developing Foralumab for liver
diseases. Foralumab is the only fully human anti-CD3 monoclonal
antibody in clinical development in the world. This Phase 2
compound has potential application in a wide range of autoimmune
and inflammatory diseases, such as nonalcoholic steatohepatitis
(NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes
(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The company is
accelerating development of anti-Interleukin 6 receptor (IL6R) mAb,
a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379
United States Investors:
Dave Gentry Office 1 800 RED CHIP (733
RedChip Companies Inc. 2447)
Cell 407-491-4498 (USA)
dave@redchip.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAELKASAFEAA
(END) Dow Jones Newswires
April 27, 2021 02:00 ET (06:00 GMT)
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tiziana Life Sciences (LSE:TILS)
Historical Stock Chart
From Jul 2023 to Jul 2024